$ENLV

Why is this trending?

Enlivex Therapeutics reported strong Q4 earnings of $25.80 per share and received FDA clearance for its Phase 2b Allocetra trial. Investors celebrated the biotech firm's solid financials and clinical progress, driving high interest in the stock. The dual strategy of treasury growth and pipeline advancement fueled optimism for 2026.